Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1)

Completed · Phase 2 · Has a placebo group

Conditions studied: Rheumatoid Arthritis Interstitial Lung Disease

In brief

The purpose of this study is to to assess the safety and tolerability of pirfenidone 2403 mg/day for the treatment of RA-associated interstitial lung disease.

Key facts

Study ID
NCT02808871
Run by
Brigham and Women's Hospital
People needed
123
Starts
2017-04-07
Expected to finish
2021-04-07
Last updated by the study team
2022-08-16

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.